Immune-Onc Therapeutics
PrivateLast Round
Series B
Extension
Jan 5, 2023
Total Funding Raised
$140.14M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immune-Onc Therapeutics is a biotechnology company that develops novel biotherapeutics targeting myeloid cell inhibitory receptors to treat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immune-Onc Therapeutics Comparables
Compare Immune-Onc Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Elpiscience Biopharmaceuticals | 84% | |
| OncoResponse | 84% | |
| ImmuneOnco Biopharmaceuticals | 83% |
Immune-Onc Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 5, 2023 | ||||
| Series B | Mar 30, 2021 | ||||
| Grant | Aug 4, 2020 | ||||
| Series B | Sep 18, 2018 | ||||
| Series A | Sep 1, 2016 |
Key People
Founding team and executive leadership
Immune-Onc Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| StartX | Series B |
| Triwise Capital | Series B Extension |
| Northern Light Venture Capital | Series B |
| Oceanpine Capital | Series B |
| 中南创投基金 | Series B |
| Leukemia & Lymphoma Society | Series B Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 81% MoM, reaching 2.8K.
- Jan 5, 2023
$25M round led by Triwise Capital.
Immune-Onc Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immune-Onc Therapeutics's valuation, stock price, and market status.
Is Immune-Onc Therapeutics a public or private company?
Immune-Onc Therapeutics is a private company.
What is the current stock price of Immune-Onc Therapeutics?
Immune-Onc Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Immune-Onc Therapeutics worth (valuation)?
Valuation information for Immune-Onc Therapeutics is not publicly available.
Can I buy Immune-Onc Therapeutics stock?
Immune-Onc Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immune-Onc Therapeutics's last funding round?
Immune-Onc Therapeutics's most recent funding round was Series B Extension on January 5, 2023.
Who are the main investors in Immune-Onc Therapeutics?
Key investors in Immune-Onc Therapeutics include Triwise Capital, Northern Light Venture Capital, Oceanpine Capital.
Will Immune-Onc Therapeutics IPO soon?
No public IPO plans have been announced for Immune-Onc Therapeutics.
How can I track Immune-Onc Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immune-Onc Therapeutics's secondary market activity and sign up for updates.